Scarica l'app Stockscreener
205.29
1.27%
2.57
Dopo l'orario di chiusura:
204.00
-1.29
-0.63%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie Inc. (ABBV): Among the Best Dividend Aristocrat Stocks with Over 3% Yield - Insider Monkey
Regulatory Condition Satisfied for License Agreement between AbbVie and Gubra - ACCESS Newswire
AbbVie Vs. Sanofi: Which Is The Better Investment Right Now (NYSE:ABBV) - Seeking Alpha
AbbVie (ABBV) Rebounds After Consecutive Losses, Eyes Future Gro - GuruFocus.com
Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week - MSN
AbbVie shares rose after seven consecutive sessions of losses (NYSE:ABBV) - Seeking Alpha
Corticosteroids Market May See a Big Move | Major Giants- AbbVie, Astellas Pharma, AstraZeneca - openPR
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
AbbVie (NYSE:ABBV) Showcases Oncology Innovations Amidst 6% Share Price Dip - Yahoo Finance
Non-Small Cell Lung Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics, AstraZeneca - Barchart
AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025 - PR Newswire
2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income - Yahoo Finance
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market - MSN
AbbVie accuses oncology partner of stealing trade secrets - Crain's Chicago Business
AbbVie Inc (ABBV) Shares Gap Down to $202.37 on Mar 25 - GuruFocus.com
Smart Money Is Betting Big In ABBV OptionsAbbVie (NYSE:ABBV) - Benzinga
AbbVie sues Genmab, claiming trade secrets theft - pharmaphorum
AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Abbvie CEO Robert A. Michael's 2024 Total Compensation Was $18.5 MillionFiling -March 24, 2025 at 04:44 pm EDT - Marketscreener.com
AbbVie lawsuit alleges that partner Genmab “misappropriated” trade secrets - PharmaLive
Genmab stock falls amid AbbVie lawsuit By Investing.com - Investing.com South Africa
Genmab to Defend Against AbbVie’s Trade Secret Misappropriation Claims - TipRanks
Genmab stock falls amid AbbVie lawsuit - Investing.com
AbbVie Lawsuit Alleges That Partner Genmab "Misappropriated” Trade Secrets - BioSpace
Genmab faces trade secret claims by AbbVie - Investing.com India
Genmab Denies Trade Secret Misappropriation Claims by AbbVie -March 24, 2025 at 08:21 am EDT - Marketscreener.com
Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025 - AbbVie
Genmab dismisses Abbvie lawsuitaccused of exploiting trade secrets -March 24, 2025 at 03:30 am EDT - Marketscreener.com
Global Autoimmune Disease Therapeutics Market to reach USD 226,194.0 Million by 2035 Amid Rising Prevalence and Advancements in Biologic Therapies | Future Market Insights, Inc. - GlobeNewswire Inc.
Is AbbVie Inc. (ABBV) The Best Healthcare Dividend Stock to Invest in? - Insider Monkey
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. - GlobeNewswire
Genmab To Vigorously Defend Alleged Claims Of Trade Secret Misappropriation By Abbvie Inc. - Marketscreener.com
Is AbbVie Gaining or Losing Market Support?AbbVie (NYSE:ABBV) - Benzinga
Non-Small Cell Lung Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca, Daiichi Sankyo - Barchart
Open Angle Glaucoma Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Visiox Pharma, TearClear, VivaVision Biotech, Inc., Abbvie, Ocuphire Pharma, Qlaris Bio, Inc - The Globe and Mail
Botox Market Demand, Growth, Demand and Future Scope 2025-2032 | - openPR
AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease - MSN
AbbVie Options Trading: A Deep Dive into Market Sentiment - Benzinga
Advancing Oncology: Innovations in Treatment and Detection - Value the Markets
Parkinson’s Disease Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail Therapeutics, Amnea - Barchart
Alzheimers Drugs Market Is Booming Worldwide | AbbVie, Inc., Teva Pharmaceuticals Ltd., Eisai Co., Ltd - openPR
Abbvie Inc. (ABBV) Elliott Wave technical analysis [Video] - FXStreet
Immunology Drugs Market Key Players AnalysisEli Lilly, AbbVie Inc, F.Hoffmann-La roche Ltd, Amgen Inc, Pfizer. - openPR
Transitional Cell Carcinoma Treatment Market Size in 7MM - openPR
AbbVie (ABBV) Stock Moves -0.29%: What You Should Know - Yahoo Finance
AbbVie CFO Scott Reents sells $3.75 million in stock By Investing.com - Investing.com Australia
AbbVie CFO Scott Reents sells $3.75 million in stock - Investing.com
Endometriosis Pain Pipeline 2025: FDA Approvals and Clinical - openPR
Widely used drugs on US imports list from Europe - Reuters.com
AbbVie upgraded to Buy at Erste Group on Friday - Yahoo Finance
AbbVie's Elahere Cuts Death Risk By 32%, Shows Consistent Survival Benefit In Long-Term Analysis For Certain Ovarian Cancer Patients - Benzinga India
AbbVie’s Elahere demonstrates extended survival in Phase 3 MIRASOL trial - World Pharmaceutical Frontiers
Erste Group lifts AbbVie stock rating to Buy on growth forecast - Investing.com UK
AbbVie reports final analysis from Phase III trial of Elahere for ovarian cancer - Yahoo Finance
The Zacks Analyst Blog Highlights AbbVie, Lockheed Martin, Dell and Hamilton Beach Brands - Nasdaq
0.36%
1.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):